Tirzepatide (Mounjaro) is prescribed off-label for PCOS. Review the dosing protocol, clinical evidence for insulin resistance and ovulation, FDA status, and what the research actually shows.
Tirzepatide (Mounjaro) is not FDA-approved for PCOS, but emerging trial data suggest meaningful improvements in ovulation, insulin resistance, and androgen levels. Here is what clinicians and patients should know about the risks and tradeoffs.
Tirzepatide (Mounjaro) is being used off-label for obstructive sleep apnea. Review the SURMOUNT-OSA trial data, dosing protocols, AHI reductions, and what clinicians should know before prescribing.
A clinical evidence summary of tirzepatide (Mounjaro) used off-label for weight loss, including trial data from SURMOUNT and SURPASS, dosing, safety, and how it compares to semaglutide.
Evidence-based guide to using oral micronized progesterone (Prometrium) off-label for insomnia, including dosing protocols, mechanism of action, clinical evidence, and safety considerations.
A clinical evidence review of oral micronized progesterone (Prometrium) used off-label for insomnia, including trial data, dosing, safety, and how it compares to standard sleep aids.
Oral micronized progesterone (Prometrium) is used off-label for insomnia. Learn the evidence, monitoring requirements, dosing, and safety considerations for this sleep aid.
Evidence-based guide to using oral micronized progesterone (Prometrium) off-label for luteal phase support, including dosing, monitoring, and clinical trial data.
Can oral micronized progesterone (Prometrium) support the luteal phase? Review the off-label evidence, dosing protocols, risks, and how it compares to vaginal and injectable progesterone.
Evidence-based guide to using oral micronized progesterone (Prometrium) off-label for perimenopause symptoms, including dosing protocols, clinical evidence, and safety considerations.
Off-label dosing is 100 to 200mg nightly for sleep; evidence is moderate with small RCTs. Includes monitoring steps and dosing guidance.
Oral micronized progesterone (Prometrium) has been studied for traumatic brain injury neuroprotection. Review the off-label dosing protocols, Phase III trial results from ProTECT III and SyNAPSe, and current evidence grading.
A clinical review of oral micronized progesterone (Prometrium) for traumatic brain injury, including Phase III trial failures, off-label considerations, neuroprotective mechanisms, and monitoring protocols.
Semaglutide (Ozempic) 0.5-2.0 mg is being explored off-label for heart failure. Review the dosing protocol, trial evidence from SELECT and STEP-HFpEF, FDA-approved indications, and what clinicians should know.
Semaglutide (Ozempic) is not FDA-approved for heart failure, but emerging trial data in HFpEF shows measurable benefits. Learn the evidence, monitoring protocols, and safety considerations for off-label use.
Semaglutide (Ozempic) 0.5-2.0 mg is being studied for kidney protection in CKD. Review the off-label evidence, dosing protocols, FLOW trial results, and clinical guidance for renal use.
Semaglutide (Ozempic) 0.5 to 2.0 mg is used off-label for NASH. Review the dosing protocol, key trial data, FDA status, and what clinicians should know before prescribing.
Semaglutide (Ozempic) is not FDA-approved for NASH/MASH, but clinical trial data shows histological improvement in liver fibrosis and steatohepatitis. Learn the risks, dosing, and evidence.
Semaglutide (Ozempic) is used off-label for PCOS to improve insulin resistance, restore ovulation, and reduce androgen levels. Learn the dosing protocol, evidence base, and what clinicians should discuss with patients.
A evidence summary of off-label semaglutide (Ozempic) for polycystic ovary syndrome (PCOS), covering trial data on weight, androgens, ovulation, and insulin resistance.
Ozempic (semaglutide 0.5-2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. Here's what the clinical trials show about off-label use, real risks, and how it compares to the approved weight-loss dose.
A clinical evidence summary of bremelanotide (PT-141) for male sexual dysfunction, including trial data, dosing, safety, and off-label status.
MAESTRO-NASH data: resmetirom 100mg resolved NASH in 29.9% vs 9.7% placebo at 52 weeks; FDA-approved, not off-label, for F2-F3 fibrosis.
Liraglutide 3 mg (Saxenda) is being studied off-label for alcohol use disorder. This evidence summary covers preclinical data, early clinical trials, mechanism of action, and what clinicians should know.
Liraglutide 3 mg (Saxenda) is sometimes used off-label for binge eating disorder. This article reviews the evidence, dosing protocol, safety considerations, and how it compares to FDA-approved BED treatments.
Can liraglutide 3 mg (Saxenda) treat binge eating disorder? Review of clinical trials, dosing, off-label evidence, and what the research actually shows about GLP-1 receptor agonists for BED.
Can Saxenda (liraglutide 3 mg) treat binge eating disorder? Review the off-label evidence, clinical trial data, risks, and how GLP-1 receptor agonists affect binge eating behavior.
Liraglutide 3 mg (Saxenda) is used off-label for NASH. Review the dosing protocol, LEAN trial evidence, histological outcomes, and practical clinical considerations.
Sermorelin acetate is used off-label for adult growth hormone deficiency. This guide covers the evidence, risks, dosing, and how it compares to FDA-approved recombinant GH therapy.
A clinical review of sermorelin acetate for sleep improvement, including its off-label status, the link between growth hormone and sleep architecture, and what published trials report.
TB-500 (thymosin beta-4 active fragment) is used off-label for wound healing. Review the preclinical evidence, proposed dosing protocols, safety considerations, and FDA status.
A clinical evidence review of TB-500 (thymosin beta-4 active fragment) for wound healing, including preclinical data, off-label use context, dosing protocols, and safety considerations.
Evidence-based guide to off-label testosterone cypionate use in frailty syndrome, covering dosing protocols, clinical trial data, safety monitoring, and guideline recommendations.
Evidence-based guide to off-label testosterone cypionate use in gender-affirming hormone therapy, including dosing protocols, monitoring, and clinical outcomes.
A clinical evidence summary of testosterone cypionate used off-label for gender-affirming hormone therapy, including dosing, outcomes, safety data, and guideline recommendations.
Testosterone cypionate is widely used off-label for gender-affirming hormone therapy. Learn about evidence, dosing, risks, monitoring, and what the Endocrine Society guidelines recommend.
Evidence-based guide to off-label testosterone cypionate use in HIV wasting syndrome, including dosing protocols, clinical trial data, and monitoring requirements.
Testosterone cypionate is used off-label for HIV-associated wasting syndrome. Review the clinical evidence, dosing protocols, risks, and how it compares to FDA-approved therapies.
Can semaglutide 2.4 mg (Wegovy) treat alcohol use disorder? Review the preclinical and early clinical evidence, proposed dosing protocols, and what physicians should know before prescribing off-label.
Semaglutide 2.4 mg (Wegovy) is being used off-label for binge eating disorder. Review the clinical evidence, monitoring protocols, and what patients and clinicians should track during treatment.
A clinical review of semaglutide 2.4 mg (Wegovy) used off-label for binge eating disorder, including trial data, risk-benefit analysis, and practical prescribing considerations.
A clinical evidence review of semaglutide 2.4 mg (Wegovy) for nonalcoholic steatohepatitis (NASH/MASH), covering phase 2 and phase 3 trial data, mechanism of action, GRADE-level assessment, and practical prescribing considerations.
Semaglutide 2.4 mg (Wegovy) is used off-label for NASH/MASH. Learn the clinical trial evidence, monitoring schedule, liver enzyme targets, and what your provider should track.
Zepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn about its off-label use for type 2 diabetes, the clinical evidence from SURPASS trials, and the monitoring your clinician should follow.
Zepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn the evidence behind off-label use for type 2 diabetes, how it compares to Mounjaro, risks, and what clinicians consider before prescribing.
A clinical evidence review of tirzepatide (Zepbound) for heart failure, covering trial data from SUMMIT and STEP-HFpEF, FDA-approved indications, and what the research shows about cardiac outcomes.
Tirzepatide (Zepbound) is not FDA-approved for heart failure. Trial evidence in HFpEF with obesity shows symptom and functional improvement, but not proven reductions in hospitalization or death. Here is what the evidence supports, what remains unproven, and what monitoring off-label use requires.
Can Zepbound (tirzepatide) treat heart failure? Review the off-label evidence from SURMOUNT-HFpEF trials, FDA-approved indications, cardiovascular risks, and what clinicians consider before prescribing.
Tirzepatide (Zepbound) is not FDA-approved for PCOS, but clinicians are using it off-label based on its weight-loss and insulin-sensitizing effects. Here is what is established, what is plausible but unproven, and what monitoring is reasonable before and during treatment.
What the FDA label and clinical evidence actually support for oral micronized progesterone (Prometrium) dosing in adults 30 to 49, including cyclic versus continuous regimens, off-label uses, monitoring, and when to escalate care.
A clinical review of oral micronized progesterone (Prometrium) safety in adults aged 30 to 49, covering side effects, cardiovascular risk, breast safety, drug interactions, and monitoring guidelines.
A detailed cost and clinical comparison of oral micronized progesterone (Prometrium) against medroxyprogesterone acetate, norethindrone acetate, levonorgestrel IUD, and compounded progesterone for HRT endometrial protection.
Evidence-based guide to every clinically significant drug-drug interaction with oral micronized progesterone (Prometrium), including CYP3A4 inhibitors, inducers, CNS depressants, and hormone therapy combinations.
A clinical review of upcoming oral micronized progesterone formulations, novel delivery systems, and pipeline developments including TX-001HR, segesterone acetate combinations, and extended-release progesterone technologies.
A clinical history of oral micronized progesterone (Prometrium), from early extraction failures through micronization technology, the PEPI trial, and modern HRT guidelines.
Kaiser Permanente coverage details for oral micronized progesterone (Prometrium), including formulary tier, prior authorization requirements, step therapy, appeal options, and cost-saving alternatives.
Oral micronized progesterone binds PR-A/PR-B to trigger secretory changes, plus how its allopregnanolone metabolite acts on GABA-A receptors for sedation.
Medicare Advantage plans generally cover oral micronized progesterone (Prometrium) for endometrial protection during HRT. Learn about formulary tiers, prior authorization, step therapy, and how to appeal a denial.
Evidence-based monitoring guide for oral micronized progesterone (Prometrium) in adults aged 50 to 64 on HRT, covering labs, imaging, safety checks, and follow-up intervals.
A clinical review of the Prometrium patent history, generic progesterone availability, and what prescribers need to know about current formulation options and upcoming developments.